Update on immunologic therapy with anti–CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events …
KC Kaehler, S Piel, E Livingstone, B Schilling… - Seminars in …, 2010 - Elsevier
Immune-modifying monoclonal antibodies may induce or enhance the natural immune
response against tumor cells. The complex interaction between antigen-presenting cells and
T lymphocytes as an immune response is strongly affected by anti-CD152 (cytotoxic T-
lymphocyte antigen-4, CTLA-4)-antibodies. However, specific CTLA-4 antibodies can block
the CTLA-4 receptor and thus induce an unrestrained T-cell activation. To this stage,
treatment of patients with metastatic melanoma with the CTLA-4 antibodies ipilimumab and …
response against tumor cells. The complex interaction between antigen-presenting cells and
T lymphocytes as an immune response is strongly affected by anti-CD152 (cytotoxic T-
lymphocyte antigen-4, CTLA-4)-antibodies. However, specific CTLA-4 antibodies can block
the CTLA-4 receptor and thus induce an unrestrained T-cell activation. To this stage,
treatment of patients with metastatic melanoma with the CTLA-4 antibodies ipilimumab and …